BridgeBio to Unveil Key Data on Infigratinib for Achondroplasia at ESPE 2026
Event summary
- BridgeBio will present late-breaking oral data on infigratinib for achondroplasia at ESPE 2026 on September 9.
- Three additional posters and one ePoster will cover longer-term data, pediatric studies, and hypochondroplasia research.
- Infigratinib targets FGFR3 signaling to address skeletal dysplasias like achondroplasia and hypochondroplasia.
- Achondroplasia affects ~55,000 people in the U.S. and EU, with significant unmet medical needs.
The big picture
BridgeBio’s presentation at ESPE 2026 underscores the growing focus on genetic conditions with limited treatment options. The company’s decentralized model aims to streamline drug development for rare diseases, but success hinges on demonstrating sustained clinical benefits. The broader biopharmaceutical sector is watching closely, as breakthroughs in skeletal dysplasias could set a precedent for other orphan drug markets.
What we're watching
- Clinical Efficacy
- How the PROPEL 3 data will position infigratinib against existing and emerging therapies for achondroplasia.
- Regulatory Pathway
- Whether BridgeBio can leverage these results to accelerate approval timelines for infigratinib.
- Market Expansion
- The pace at which BridgeBio can expand infigratinib’s use into related skeletal dysplasias like hypochondroplasia.